Literature DB >> 21527769

Frequency of increased blood pressure levels during systemic thrombolysis and risk of intracerebral hemorrhage.

Lars Kellert1, Andrea Rocco, Marek Sykora, Werner Hacke, Peter A Ringleb.   

Abstract

BACKGROUND AND
PURPOSE: Significantly increased blood pressure (BP) is common in patients receiving intravenous thrombolysis (IVT). We aimed to investigate frequency of pre- and post-treatment elevated BP and its relation to intracerebral hemorrhage (ICH) and symptomatic ICH (sICH), respectively.
METHODS: Data for patients treated with intravenous thrombolysis in the years 2007 to 2009 were retrospectively extracted from our prospectively conducted local stroke database. All documented BP levels from admission to follow-up imaging scan were analyzed. BP protocol violations were defined as systolic BP >185 mm Hg and/or diastolic BP >110 mm Hg. sICH was defined as ICH plus worsening of the National Institute of Health Stroke Scale ≥4 points.
RESULTS: BP protocol violation before IVT emerged in 12.6% and during the course of IVT in 40.1% of 427 patients. sICH occurred in 10 (2.3%) and ICH in general occurred in 51 (11.9%) of 427 patients. Proportions of BP protocol violations were similar in patients without ICH, with any ICH, and with sICH (3.1% versus 2.8% versus 3.2%). Systolic BP levels and mean arterial pressure did not differ between patients without ICH, patients with any ICH, and patients with sICH. In the multivariate analysis, only early CT findings independently predicted ICH (OR, 2.39; 95% CI, 1.25-4.61; P=0.009).
CONCLUSIONS: BP protocol violations are common before and during the course of IVT, but neither the frequency of BP protocol violations nor the BP levels predicted ICH or sICH in univariate or multivariate analyses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21527769     DOI: 10.1161/STROKEAHA.110.604744

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

1.  [Thrombolytic treatment of acute stroke].

Authors:  H Amiri; W Hacke; J Bösel
Journal:  Internist (Berl)       Date:  2011-11       Impact factor: 0.743

2.  Antihypertensive treatment prolongs tissue plasminogen activator door-to-treatment time: secondary analysis of the INSTINCT trial.

Authors:  Lesli E Skolarus; Phillip A Scott; James F Burke; Eric E Adelman; Shirley M Frederiksen; Allison M Kade; Jack D Kalbfleisch; Andria L Ford; William J Meurer
Journal:  Stroke       Date:  2012-10-02       Impact factor: 7.914

3.  Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.

Authors:  Eric E Adelman; Phillip A Scott; Lesli E Skolarus; Allison K Fox; Shirley M Frederiksen; William J Meurer
Journal:  J Stroke Cerebrovasc Dis       Date:  2015-09-26       Impact factor: 2.136

4.  Thyroid hemorrhage causing airway obstruction after intravenous thrombolysis for acute ischemic stroke.

Authors:  Raoul Sutter; Elisabeth Bruder; Mandy Weissenburg; Gianmarco M Balestra
Journal:  Neurocrit Care       Date:  2013-12       Impact factor: 3.210

5.  Effects of Early Changes in Blood Pressure During Intravenous Thrombolysis on the Prognosis of Acute Ischemic Stroke Patients.

Authors:  Zhong-Xiu Wang; Chao Wang; Peng Zhang; Yang Qu; Zhen-Ni Guo; Yi Yang
Journal:  Front Aging Neurosci       Date:  2020-12-04       Impact factor: 5.750

6.  Early blood pressure changes during systemic thrombolysis and its association with unexplained early neurological deterioration in small subcortical infarct.

Authors:  Xiu'e Wei; Zuowei Duan; Yujia Zhai; Cuicui Zhang; Jun Zhang; Ting Hu; Tengfei Liu; Zhenqian Liu; Jiang Xu; Haiyan Liu; Liangqun Rong
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-07-26       Impact factor: 2.885

7.  The ThRombolysis in UnconTrolled Hypertension (TRUTH) protocol: an observational study on treatment strategy of elevated blood pressure in stroke patients eligible for IVT.

Authors:  T P Zonneveld; A Algra; D W J Dippel; L J Kappelle; R J van Oostenbrugge; Y B W E M Roos; M J Wermer; H B van der Worp; P J Nederkoorn; N D Kruyt
Journal:  BMC Neurol       Date:  2015-11-23       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.